Sector
PharmaceuticalsOpen
₹117.3Prev. Close
₹116.69Turnover(Lac.)
₹22.35Day's High
₹120.98Day's Low
₹117.0552 Week's High
₹144.552 Week's Low
₹69.9Book Value
₹83.04Face Value
₹10Mkt Cap (₹ Cr.)
252.06P/E
12.2EPS
9.88Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 21.04 | 21.04 | 21.04 | 21.04 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 140.93 | 124.07 | 110.6 | 96.48 |
Net Worth | 161.97 | 145.11 | 131.64 | 117.52 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Revenue | 97.55 | 85.96 | 63.38 | 53.5 |
yoy growth (%) | 13.47 | 35.63 | 18.46 | -6.78 |
Raw materials | -59.46 | -50.99 | -36.32 | -27.87 |
As % of sales | 60.95 | 59.31 | 57.3 | 52.1 |
Employee costs | -11.74 | -11.82 | -8.61 | -7.17 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Profit before tax | 10.79 | 5.07 | 11.21 | 10.63 |
Depreciation | -1.22 | -1.14 | -0.76 | -0.83 |
Tax paid | -3.52 | -0.99 | -3.11 | -2.89 |
Working capital | 12.44 | -45.41 | -11.88 | -8.27 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 13.47 | 35.63 | 18.46 | -6.78 |
Op profit growth | 123.3 | -51.39 | 4.2 | 99.33 |
EBIT growth | 106.38 | -59.18 | 7.04 | 8,435.12 |
Net profit growth | 78.13 | -31.91 | -22.6 | -654.09 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 108.74 | 92.44 | 112.27 | 97.55 | 85.97 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 108.74 | 92.44 | 112.27 | 97.55 | 85.97 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 14.89 | 9.93 | 10.78 | 4.4 | 2.91 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,800.05 | 156.54 | 4,31,544.39 | 863.29 | 0.75 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,210.55 | 89.74 | 1,64,865.28 | 518 | 0.48 | 2,302 | 513.62 |
Cipla Ltd CIPLA | 1,533.9 | 29.27 | 1,23,920.06 | 1,178.16 | 0.85 | 3,969.86 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,363.1 | 69.54 | 1,13,766.71 | 460 | 0.83 | 2,376 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,559 | 51.15 | 1,02,527.44 | 634.43 | 0 | 2,529.74 | 269.23 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Exec. Director
Mahendra Singh Chawla
Executive Director
Pravin C Shah
Independent Director
Sharad Chand Lunawat
Independent Director
Devendra Baheti
Independent Director
Krishna Das Malani
Managing Director
Paresh Chawla
Independent Director
Jyoti Jain
Executive Director
Vitthal Kothana
Additional Director
SUNIL VALECHA
Independent Director
Saket Baheti
Independent Director
Pratibha Lunawat
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Alpa Laboratories Ltd
Summary
M/s Alpa Laboratories, formed in 1967, was incorporated as Private Limited Company in the name of Alpa Laboratories Private Limited on March 18, 1988 for manufacture of pharmaceutical formulations. In 1998, the Company was converted into a Public Limited Company with effect from September 3, 1998 with the name of Alpa Laboratories Limited. The facility has dedicated manufacturing areas for different Finished Dosage Forms (FDFs) including liquid injections, dry injections, tablets, capsules, eye drops, ear drops, ointments, creams and gels.In 1997, the company has initiated setting of a new manufacturing unit at Rau(Indore District), Madhya Pradesh. The unit commenced commercial production in the year 1999 of all types of formulations viz. Injectables (Vials/Ampoules both liquid and Dry), tablets, capsules, eye/ear drops, ointment and creams. The company has manufacture a range of products such as ethical drugs, generic drugs, over the counter drugs (OTC) and veterinary products in various dosage forms and market them under the trade mark Alpa which is a registered trademark in the name of Alpa Labs (India) Limited, a promoter group company. The company has also manufacture formulations for a number of other pharmaceutical companies of national and international repute such as Cipla, Zydus Cadila, Lupin, Glenmark, Genom Biotech, Jenburkt, etc. (under their own brands) located both in India and abroad in countries such as Philippines, Iran, Iraq, Sierra Leon, Madagascar, Kenya,
Read More
The Alpa Laboratories Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹119.8 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Alpa Laboratories Ltd is ₹252.06 Cr. as of 04 Dec ‘24
The PE and PB ratios of Alpa Laboratories Ltd is 12.2 and 1.45 as of 04 Dec ‘24
The 52-week high/low is the highest and lowest price at which a Alpa Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Alpa Laboratories Ltd is ₹69.9 and ₹144.5 as of 04 Dec ‘24
Alpa Laboratories Ltd's CAGR for 5 Years at 50.03%, 3 Years at 26.02%, 1 Year at 19.44%, 6 Month at 43.44%, 3 Month at 12.07% and 1 Month at 5.81%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice